Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
With substantial experience in T cell receptor (TCR) engineering and TCR transfer gene therapy, Creative Biolabs provides a broad range of assay services to evaluate the antigen specific reactivity and cytotoxicity of TCR-modified T lymphocytes. Taking advantage of state-of-the-art instruments and experienced Ph.D level TCR specialists, we are capable of designing and performing custom analysis service to obtain comprehensive information about the reactivity and cytotoxicity of your specific TCRs.
Recently, an innovative immunotherapy approach involving substituting redirected T cells using predefined certain antigen-specific TCR gene transfer has shown great promise in treating multiple caners and infection diseases. Gene modified TCR therapy is employing certain delivery vehicle to transfer the α-and β-chains genes of a specific TCR into autologous or donor-derived T cells, as a result, the specificity of those T cells can be redirected and large populations of antigen-specific T cells can be generated with high avidity for the antigen of interest. A successful engineered T cell with antigen–specific TCR can harness their own cytotoxicity to the target and eradicate tumors or other diseased cells, therefore, it is critical to analyze the lymphocyte antigen reactivity and cytotoxicity (target-killing activity) with appropriate approaches, which is also an approach to evaluate the effiency of your TCR. Creative Biolabs has various assay methods available for customers to measure the antigen specificity and cytotoxicity of TCR-modified T cells. According to the fact that the activation of T lymphocytes, both in vivo and in vitro, induces expression of CD69, we strongly recommended CD69 induction assay based on the flow cytometric analysis of CD69 expression to analyze the antigen-specificity of the cloned TCR α/β pairs. Additionally, the specificity and biologic activity of TCR gene-transduced T-cells can be determined by cytokine production, using enzyme-linked immunosorbent assay (ELISA) for the detection of cytokine secretion can be an alternative approach. The ability of the transduced cells to lyse target cancer cells (cytotoxicity) can be measured by the chromium release assay and the calcein-AM release assay. Other methods suitable for the analysis of antigen specificity and cytotoxicity are also available upon request. Meanwhile, Creative Biolabs is willing to custom a one-stop evaluation procedure according to your requirement.
Customers choosing our lymphocyte antigen reactivity and cytotoxicity assay service of TCR gene-transduced T-cells will benefit from our advanced instruments and extensive expertise. We are dedicated to offer top-quality service to meet every customer's requirements.
To discuss your demands or to request a proposal, please contact us by .
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
